Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study

Table 2 Subsequent therapies

	IPI-treated cohort		Non-IPI–treated cohort
	IPI-noOther (n = 780)^a	IPI-Other (n = 314)	Other-Other (n = 205)	Other-IPI (n = 57)
Systemic therapy, no. (%)	0	313 (100)	54 (26)	57 (100)
Immunotherapy	0	181 (58)	18 (9)	57 (100)
Anti–PD-1 agent^b	0	161 (51)	18 (9)	10 (18)
Anti–CTLA-4 agent^c	0	34 (11)	0	57 (100)
Other systemic therapy, no. (%)	0	186 (59)	43 (21)	15 (26)
BRAF ± MEK inhibitor^d	0	103 (33)	18 (9)	8 (14)
Chemotherapy^e	0	110 (35)	33 (16)	12 (21)
Other investigational agent^f	0	11 (4)	1 (<1)	0
Other^g	0	11 (4)	0	0
Radiotherapy^h	138 (18)	101 (32)	21 (10)	16 (28)

CTLA-4 cytotoxic T-lymphocyte antigen 4, IPI ipilimumab, PD-1 programmed death 1.
^aRadiotherapy was allowed with ipilimumab in this cohort; therefore, it was not considered subsequent therapy
^bPembrolizumab or nivolumab
^cIpilimumab
^dDabrafenib ± trametinib or vemurafenib ± cobimetinib
^eBleomycin, carboplatin, cisplatin, combinations of antineoplastic agents, cyclophosphamide, dacarbazine, dactinomycin, docetaxel, etoposide, fotemustine, gemcitabine, lomustine, melphalan, paclitaxel, paclitaxel + carboplatin, temozolomide, treosulfan, trofosfamide, vinblastine, vincristine, vindesine, or vinorelbine
^fBevacizumab or imatinib
^gAldesleukin, antineoplastic and immunomodulating agents, interferon-alpha, interleukin-2, melanoma vaccine, other therapeutic products, or monoclonal antibodies
^hRadiation, radiosurgery, radiotherapy, or yttrium (⁹⁰Y)

ISSN: 1471-2407